OR WAIT null SECS
Novozymes Biopharma will introduce its hyaluronic acid (HA) eye care product at the 2011 Joint Congress of the European Society of Ophthalmology (SOE), Geneva, Switzerland, 4?7 June 2011.
Novozymes Biopharma will introduce its hyaluronic acid (HA) eye care product at the 2011 Joint Congress of the European Society of Ophthalmology (SOE), Geneva, Switzerland, 4–7 June 2011.
The Bacillus-derived product for ophthalmic drug delivery reportedly prolongs drug reaction time, provides high viscosity profiles for ease of application, increased patient comfort and high heat resistance. Additionally, the company claims the HA product can dissolve up to five times faster than other drug delivery compounds.
Hans Ole Klingenberg, Global Marketing Director at Novozymes Biopharma, said: “We are proud to showcase our innovative HA product which, due to its high purity and biocompatibility is ideally suited for use in formulations intended for eye care and ophthalmic drug delivery. We are also delighted to present the results of our latest study into the use of HA in ophthalmology, which provides insight into the increasing need for a high purity HA ingredient for ophthalmic applications.”
The high purity, biocompatible HA doesn't create corneal lesions and is compatible with confocal laser treatment. Later this year Novozymes will build a facility specializing in the production of HA.